Abstract
SARS-CoV-2 infection leads to a heterogenous spectrum of clinical conditions ranging from self-limiting upper airway infection to severe respiratory failure. Carbocysteine is a thioether mucolytic with antioxidant and anti-inflammatory activities. Carbocysteine has been shown to have anti-viral effects on human rhinovirus, RSV and the influenza virus as well as interfering with upper airway ciliary motility, the first site of SARS-CoV-2 infection, leading to more effective mucus clearance and potential containment of viral spread towards the lower airway. Positive effects, in terms of limiting superimposed bacterial infection and reducing oxidative stress, have also been documented in COPD patients. Accordingly, Carbocysteine should also be considered in both post-exposure prophylaxis and early-phase treatment of COVID-19 in combination with other agents (monoclonal antibodies, antivirals, non-steroidal anti-inflammatory agents, and inhaled corticosteroids). In this review, we explored the pharmacokinetic and pharmacodynamic aspects of Carbocysteine to delineate its potential therapeutic impact in patients with COVID-19.
Subject
Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics
Reference88 articles.
1. Perrotta, F., Matera, M.G., Cazzola, M., and Bianco, A. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?. Respir. Med., 2020. 168.
2. ACE2: The Major Cell Entry Receptor for SARS-CoV-2;Scialo;Lung,2020
3. Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., and Wen, C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front. Immunol., 2020. 11.
4. Anticoagulant treatment in COVID-19: A narrative review;Carfora;J. Thromb. Thrombolysis,2021
5. COVID-19 and coagulative axis: Review of emerging aspects in a novel disease;Boccia;Monaldi Arch. Chest Dis.,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献